The emergence of the drug is fueling considerable optimism within the scientific world. This innovative antibody appears to slow the decline of memory impairment associated with early Alzheimer's disease, offering a possible change for individuals and families struggling with this challenging illness. While hurdles remain, and ongoing investigat… Read More

The evolution of Ontuxizumab, initially identified as MORAb-004, signifies a notable effort in antibody therapy. The team at the company began research on a engineered monoclonal antibody targeting CD3, focused the purpose of redirecting immune cells to destroy tumor tissue. Early investigational trials demonstrated efficacy in certain tumors, p… Read More